Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality

Cancer Genetics

Volumn 205, Issue 10, 2012, Pages 523-527

  Gerrie, Alina S ^a   Bruyere, Helene ^b   Chan, Mary Joyce ^b   Dalal, Chinmay B ^c   Ramadan, Khaled M ^a   Huang, Steven J T ^b   Toze, Cynthia L ^a,c   Gillan, Tanya L ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Chronic lymphocytic leukemia; Deletion 13q; Immunoglobulin heavy chain; Prognosis; Translocation

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q; CHROMOSOME DELETION 13; CHROMOSOME DELETION 13Q; CHROMOSOME DELETION 17P; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN HEAVY CHAIN GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX; TREATMENT FREE SURVIVAL; TRISOMY 12;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CYTOGENETICS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; TIME FACTORS; TRANSLOCATION, GENETIC; VIDARABINE;

EID: 84867671629     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.05.011     Document Type: Article

References (18)

1. Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
2. Grever M.R., Lucas D.M., Dewald G.W., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007, 25:799-804.
3. Zenz T., Mertens D., Döhner H., et al. Importance of genetics in chronic lymphocytic leukemia. Blood reviews 2011, 25:131-137.
4. Van Dyke D.L., Shanafelt T.D., Call T.G., et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 2009, 148:544-550.
5. Cavazzini F., Hernandez J.A., Gozzetti A., et al. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol 2008, 142:529-537.
6. Haferlach C., Dicker F., Weiss T., et al. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes Cancer 2010, 49:851-859.
7. Lu G., Kong Y., Yue C. Genetic and immunophenotypic profile of IGH@ rearrangement detected by fluorescence in situ hybridization in 149 cases of B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010, 196:56-63.
8. Qiu H.X., Xu W., Cao X.S., et al. Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation. Leuk Lymphoma 2008, 49:1887-1892.
9. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
10. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
11. Gerrie A.S., Toze C.L., Ramadan K.M., et al. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. Leuk Lymphoma 2012, 53:77-82.
12. British Columbia Cancer Agency. BC Cancer Agency cancer management guidelines: chronic leukemia. Available at: Accessed on February 15, 2012. http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Lymphoma/ChronicLeukemia.htm.
13. Stilgenbauer S., Sander S., Bullinger L., et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007, 92:1242-1245.
14. Cavazzini F., Rizzotto L., Sofritti O., et al. Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients. Leuk Lymphoma 2011, 53:83-88.
15. Nowakowski G.S., Dewald G.W., Hoyer J.D., et al. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol 2005, 130:36-42.
16. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002, 99:15524-15529.
17. Klein U., Lia M., Crespo M., et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010, 17:28-40.
18. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944-13949.